On August 24, 2007 the Company laid off almost all of its employees and discontinued its Neurovax multiple sclerosis trial which was being enrolled in Eastern Europe. The Company has hired a broker and is attempting to sell its HIV manufacturing assets and intellectual property. The proceeds from the sale of these assets will be used to pay its secured and unsecured creditors. The Company is evaluating strategic options related to its autoimmune technology.
Users browsing this forum: No registered users